Catalent, Inc. Closes Secondary Public Offering Of Common Stock

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the closing of the previously announced registered underwritten secondary public offering of its common stock by certain of its stockholders (the “Selling Stockholders”). The Selling Stockholders sold a total of 27,255,000 shares of Catalent’s common stock at a price to the public of $29.50, including 3,555,000 shares sold pursuant to the over-allotment option granted to the underwriters by the Selling Stockholders in connection with the offering, which was exercised in full. Catalent did not sell any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC